Table 4 Net reclassification improvement and integrated discrimination improvement of pediatric inflammatory bowel disease with hsCRP and with and without two molecular lipids, LacCer(d18:1/16:0) and PC(18:0p/22:6), using the prevalence of IBD (68%) in the validation cohort

From: Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease

 

No. of patients

Reclassified (%)

 

CRP+lipids classify as SC

CRP + lipids classify as IBD

Total

Downward (%)

Upward (%)

Net reclassified (%)

Cases with IBD

      

CRP classifies as SC

12

14

26

6%

18%

11%

CRP classifies as IBD

5

49

54

Total

17

63

80

Symptomatic controls

      

CRP classifies as SC

25

1

26

16%

3%

-14%

CRP classifies as IBD

6

5

11

Total

31

6

37

NRI (SE, P value)

0.25 (0.09, P = 0.006)

IDI (SE, P value)

0.24 (0.04, P < 0.001)

  1. hsCRP high sensitivity C-reactive protein; lactosyl ceramide (d18:1/16:0), LacCer(d18:1/16:0); phosphatidylcholine (18:0p/22:6), PC(18:0p/22:6); NRI net reclassification index, IDI integrated discrimination index, SE standard error.
Back to article page